Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Bioavailability of BI 144807 Given Alone and in Combination With Ketoconazole in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 144807
Drug: Ketoconazole

First Posted Date: 2012-10-16

Last Posted Date: 2013-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT01707940

Locations: 🇩🇪
1313.7.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Trajenta tablet

First Posted Date: 2012-10-16

Last Posted Date: 2019-01-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 3219

Registration Number: NCT01707147

Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: BI 201335 NA 120 mg capsule
Drug: BI 201335 NA 40 mg capsule

First Posted Date: 2012-10-12

Last Posted Date: 2015-07-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT01704846

Locations: 🇯🇵
1220.53.08101 Boehringer Ingelheim Investigational Site, Sumida-ku,Tokyo, Japan

A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium (high dose) + Olodaterol
Drug: Tiotropium (low dose) + Olodaterol

First Posted Date: 2012-10-11

Last Posted Date: 2015-07-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT01703845

Locations: 🇯🇵
1237.24.24001 Boehringer Ingelheim Investigational Site, Toshima-ku, Tokyo, Japan

Study to Investigate the Relative Bioavailability, Influence of Pantoprazole Coadministration and Food Effect of Different Oral Formulation of BI 113608

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: pantoprazole 40 mg STADA
Drug: BI 113608 PIB
Drug: BI 113608

First Posted Date: 2012-10-11

Last Posted Date: 2017-01-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT01703858

Locations: 🇩🇪
1314.3.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Linagliptin
Drug: Glimepiride

First Posted Date: 2012-10-10

Last Posted Date: 2015-01-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 42

Registration Number: NCT01703286

Locations: 🇩🇪
1218.105.001 Boehringer Ingelheim Investigational Site, Neuss, Germany

Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller Medication

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Tiotropium 5 mcg qd
Drug: Tiotropium 2.5 mcg bid

First Posted Date: 2012-09-28

Last Posted Date: 2014-08-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 98

Registration Number: NCT01696071

Locations: 🇩🇪
205.441.49003 Boehringer Ingelheim Investigational Site, Frankfurt, Germany
🇩🇪
205.441.49015 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇩🇪
205.441.49014 Boehringer Ingelheim Investigational Site, Frankfurt, Germany

and more 19 locations

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium
Drug: Placebo matching Olodaterol
Drug: Olodaterol

First Posted Date: 2012-09-28

Last Posted Date: 2014-11-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1137

Registration Number: NCT01696058

Locations: 🇺🇸
1222.52.02068 Boehringer Ingelheim Investigational Site, Chesterfield, Missouri, United States
🇺🇸
1222.52.02035 Boehringer Ingelheim Investigational Site, Henderson, Nevada, United States
🇺🇸
1222.52.02091 Boehringer Ingelheim Investigational Site, Syracuse, New York, United States

and more 91 locations

Investigation of Food Effect and Gastric ph Increase on the Bioavailability of Faldapravir

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: faldaprevir
Drug: omeprazole

First Posted Date: 2012-09-27

Last Posted Date: 2015-07-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT01694706

Locations: 🇩🇪
1220.59.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Olodaterol
Drug: Placebo matching Olodaterol
Drug: Tiotropium

First Posted Date: 2012-09-27

Last Posted Date: 2014-09-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1134

Registration Number: NCT01694771

Locations: 🇺🇸
1222.51.01079 Boehringer Ingelheim Investigational Site, Tamarac, Florida, United States
🇺🇸
1222.51.01076 Boehringer Ingelheim Investigational Site, Austell, Georgia, United States
🇺🇸
1222.51.01041 Boehringer Ingelheim Investigational Site, San Diego, California, United States

and more 87 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy